Android, Metandren , Testred, Virilon
Classifications: hormone; androgen/anabolic steroid; Therapeutic: anabolic steroid
Pregnancy Category: X
Controlled Substance: Schedule III
10 mg, 25 mg tablets
Short-acting steroid with androgen/anabolic activity ratio (1:1) similar to that of testosterone but less effective than
its esters. Fails to produce full sexual maturation when administered to preadolescent male with complete testicular failure
unless preceded by testosterone therapy.
Androgen activity is similar to testosterone; used in replacement therapy, and palliative treatment of postmenopausal female
Androgen replacement therapy, delayed puberty (male), palliation of female mammary cancer (15 y postmenopausal), postpartum
Liver dysfunction; prostate cancer; severe cardiac, renal, or hepatic disease; pregnancy (category X), lactation.
Mild or moderate liver, kidney, or cardiac dysfunction; heart failure, diabetes mellitus; prostatic hypertrophy.
Route & Dosage
Adult: PO 1050 mg/d in divided doses
Adult: PO 50200 mg/d in divided doses for duration of therapeutic response or no longer than 3 mo if no remission
Postpartum Breast Engorgement
Adult: PO 80 mg/d for 35 d
- Place buccal tablets between cheek and gum. Ensure that tablet is absorbed, not chewed or swallowed; and eating or drinking
avoided until absorption is complete.
- Store at 15°30° C (59°86° F). Avoid freezing.
Adverse Effects (≥1%)GI: Cholestatic hepatitis with jaundice,
irritation of oral mucosa
with buccal administration
. Urogenital: Renal
calculi (especially in immobilized patient), priapism. Endocrine: Acne, gynecomastia, edema,
oligospermia, menstrual irregularities.
Increases risk of bleeding associated with oral anticoagulants
; possibly increases risk of cyclosporine toxicity
; may decrease glucose level, making adjustment of doses of insulin, sulfonylureas
necessary. Herbal: Echinacea
may increase risk of hepatotoxicity.
Readily from GI tract. Metabolism:
In liver. Elimination:
Assessment & Drug Effects
- Lab tests: Monitor liver function periodically; report signs of hepatic toxicity (see Appendix F).
- Monitor for flank pain, abdominal pain radiating to groin, or other symptoms of renal calculi.
Patient & Family Education
- Be prepared for distressing and undesirable adverse effects of virilization (women) since dosage sufficient to produce remission
in breast cancer is quantitatively similar to that used for androgen replacement in the male.
- Report signs of virilism promptly. Voice change and hirsutism may be irreversible, even after drug is withdrawn.
- Report priapism (men) or other signs of excess sexual stimulation. The physician will terminate therapy.
- Report symptoms of jaundice with or without pruritus to physician; appears to be dose related. If liver function tests are
altered at the same time, this drug will be withdrawn.